Nurix Therapeutics, Inc.
NRIX
$15.60
-$0.13-0.83%
NASDAQ
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.62% | -38.32% | -25.65% | -43.99% | -34.47% |
| Total Depreciation and Amortization | 20.68% | 18.96% | 19.34% | 18.56% | 23.45% |
| Total Amortization of Deferred Charges | -53.85% | -7.14% | -7.14% | -7.14% | -7.14% |
| Total Other Non-Cash Items | 20.79% | 6.21% | -10.29% | -17.60% | -20.31% |
| Change in Net Operating Assets | -71.71% | -174.05% | -274.84% | -177.88% | -191.45% |
| Cash from Operations | -44.55% | -137.16% | -123.91% | -156.09% | -112.11% |
| Capital Expenditure | -51.00% | -12.54% | -7.57% | -9.61% | -10.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 165.15% | 114.54% | 29.47% | -366.47% | -423.90% |
| Cash from Investing | 157.37% | 105.10% | 25.28% | -405.08% | -477.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -50.86% | -28.76% | 2.77% | 14,350.33% | 14,997.36% |
| Repurchase of Common Stock | -- | 100.00% | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -50.86% | -28.76% | 2.77% | 14,349.88% | 14,996.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 147.48% | -136.20% | -156.25% | 60.71% | 662.30% |